Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2007
03/15/2007US20070060615 Method of Modulating Apoptosis Through Modulation of E2F1
03/15/2007US20070060614 suberoylanilide hydroxamic acid (SAHA); anticarcinogenic agent; histone deacetylase inhibitor; selectively inducing terminal differentiation, cell growth arrest, apoptosis of neoplastic cells; oral bioavailability
03/15/2007US20070060613 N-(4-(6,7-Dimethoxyquinolin-4-yloxy)-3-fluorophenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; inhibit the protein tyrosine kinase activity of growth factor receptors such as c-Met, thereby making them useful as anti-cancer agents
03/15/2007US20070060612 Antitumor agents
03/15/2007US20070060611 Method of treating or inhibiting the development of brain inflammation and sepsis
03/15/2007US20070060610 Methods and pharmaceutical formulations for increasing bioavailability
03/15/2007US20070060609 Identification and Use of Growth Hormone Secretagogue Receptor Type 1A Antagonists
03/15/2007US20070060608 Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
03/15/2007US20070060607 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives
03/15/2007US20070060606 Compounds and methods for modulating phosphodiesterase 10A
03/15/2007US20070060605 Compositions and methods for inhibiting platelet activation and thrombosis
03/15/2007US20070060604 Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment
03/15/2007US20070060603 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
03/15/2007US20070060602 [4-(2-bromo-4 isopropyl-phenyl)-6-methyl-1-(1-propyl-butyl)-1H-1,5,7b-triaza-cyclopenta[cd]inden-2-ylidene]-methyl-amine hydrochloride; corticotropin releasing factor receptor antagonist; antidepressant, anxiolitic agent; drug abuse, hypotensive, analgesic, antiinflammatory agent
03/15/2007US20070060601 Mitotic kinesin inhibitors
03/15/2007US20070060600 4-Anilinequinazolines with adenosine-kiase inhibitor properties
03/15/2007US20070060599 Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
03/15/2007US20070060598 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
03/15/2007US20070060597 Crystalline forms of 5-Chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts
03/15/2007US20070060596 Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 1-({5-bromo-2-[(phenylmethyl)oxy]phenyl}methyl)-5-methyl-1H-pyrazole-3-carboxylic acid
03/15/2007US20070060595 Novel fused heterocyclic compound and use thereof
03/15/2007US20070060594 Pyridinyl acetonitriles
03/15/2007US20070060593 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3
03/15/2007US20070060592 Chemokine receptor antagonists and methods of use therefor
03/15/2007US20070060591 Amine substituted (dihydro- or tetrahydro-)quinoline, pyranopyridine, thiapyranopyridine, or naphthyridine derivatives as chemokine receptor modulators; lymphadenopathy associated, human T-cell leukemia/lymphoma, and/or feline immunodeficiency virus infections
03/15/2007US20070060590 osteoporosis and fracture; Prostaglandin E2 derivatives specially EP4 receptor agonists; ethyl 3-{4-[(2-{3-oxo-4-[3-(trifluoromethyl)phenyl]butyl}-6-oxotetrahydropyridazin-1-yl)methyl]phenyl}acrylate
03/15/2007US20070060589 Inhibitors of protein arginine methyl transferases
03/15/2007US20070060588 Fused bicycloheterocycle substituted quinuclidine derivatives
03/15/2007US20070060587 Indane derivates as muscarinic receptor agonists
03/15/2007US20070060586 Nitrooxyderivatives of antihypertensive drugs
03/15/2007US20070060585 2-[1-Phenyl-2-(2-trifluoromethyl-phenyl)-ethyl]-morpholine-4-carboxylic acid benzyl ester, for example; for the treatment of disturbances of vegetative function associated with affective, anxiety and cognitive disorders
03/15/2007US20070060584 Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
03/15/2007US20070060583 2-tert-Butyl-N,N-diethyl-1-{[1-methylpiperidin-2-yl]methyl}-1H-benzimidazole-5-carboxamide; cannabinoid receptors agonists; analgesic, anticarcinogenic, antiinflammatory, anxiolytic agent; neurodegenerative diseases; gastrointestinal and cardiovascular disorders
03/15/2007US20070060582 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
03/15/2007US20070060581 1-Sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands
03/15/2007US20070060580 (8-{4-[3-(5 -Fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one), for example; useful as modulator of one or more G-protein coupled receptors; for treating or lessening the severity of disorders selected from Parkinson's disease, psychoses depression, anxiety
03/15/2007US20070060578 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
03/15/2007US20070060577 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
03/15/2007US20070060576 Process for preparing benzimidazole thiophenes
03/15/2007US20070060575 such as (7aR)-2-amino-3-methyl-6-pyrimidin-2-yl-7a-(4-pyrimidin-5-ylthiophen-2-yl)-5,7-dihydro-4aH-pyrrolo[3,4-d]pyrimidin-4-one, used for treating cardiovascular diseases, cognitive and neurodegenerative diseases
03/15/2007US20070060574 Phenyl-piperazine derivatives as serotonin reuptake inhibitors
03/15/2007US20070060573 Acyltryptophanols
03/15/2007US20070060572 e.g., 2-(5-fluoro-2-tolyl)-4-(4-aminocarbonylpiperazinylmethyl)-6-[a-aminocarbonyl-2,6-dichlorobenzyl]pyridine; mitogen-activated protein kinase inhibitor; antiinflammatory agent, autoimmune diseases
03/15/2007US20070060571 e.g. 4-(5-(4-Chlorophenyl)-3-((nitrooxy)methyl)-3-hydropyrazolyl)benzenesulfonamide and nitric oxide donor (S-nitrosothiols, nitrites, nitrates, N-oxo-N-nitrosamines, sabstrate of nitric oxide synthase); analgesics, antiinflammatory agent, wound healing; gastrointestinal disorders; side effect reduction
03/15/2007US20070060570 Sulfopyrroles
03/15/2007US20070060569 Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors
03/15/2007US20070060568 5HT2c receptor modulators
03/15/2007US20070060567 Novel indolyl derivatives which are L-CPT1 inhibitors
03/15/2007US20070060566 Benzazepine derivatives as histamine h3 antagonists
03/15/2007US20070060565 Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
03/15/2007US20070060564 Method of making antitussive medicine and relieving cough
03/15/2007US20070060563 Quinuclidine derivatives binding to mucarinic m3 receptors
03/15/2007US20070060562 Novel crystal form of pyrrolidylthiocarbapenem derivative
03/15/2007US20070060561 Proteasome inhibiting beta-lactam compounds
03/15/2007US20070060560 Process for producing the dihydrochloride of amino acids
03/15/2007US20070060559 2 Alpha-methyl-2 beta-[(1,2,3-triazol-1-yl)methyl]penam-3 alpha -carboxylic acid benzhydryl ester(TMPB) crystals can be efficiently precipitated from acetone, thereby not allowing contamination with by-product cepham compounds; intermediate for synthesizing tazobactam
03/15/2007US20070060558 Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents
03/15/2007US20070060557 Use of pentaazacycle Manganese(II) complexes
03/15/2007US20070060556 Barium salt of benzimidazole derivative
03/15/2007US20070060555 antiinflammatory agent, antihistamines, immunosuppressant; docosapentaenoic acid ester glucocorticoid; rhinitis, asthma, chronic obstructive pulmonary disease; inhalation; local or topical administration
03/15/2007US20070060554 Fungal and bacterial infection medication
03/15/2007US20070060553 3-Nitrogen-6,7-dioxygen steroids and uses related thereto
03/15/2007US20070060552 Methods and compositions employing 4-aminophenylacetic acid compounds
03/15/2007US20070060551 Methods of using isothiazole derivatives to treat cancer or inflammation
03/15/2007US20070060550 Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
03/15/2007US20070060549 Treating or inhibiting hypertension in a diabetic patient by administering a therapeutically effective amount of an ACE inhibitor and pyridoxal-5'-phosphate, salts thereof, or mixtures thereof, wherein the pyridoxal-5'-phosphate is in a range of 225-500 mg per dose; treatment of diabetic hypertension
03/15/2007US20070060548 Modulation of Epac, phospholipase Cepsilon, and phospholipase D to treat pain
03/15/2007US20070060547 (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis
03/15/2007US20070060546 Novel use of mifepristone and derivatives therefor as hedgehog protein signaling pathway modulators and applications of same
03/15/2007US20070060545 Novel compounds
03/15/2007US20070060544 4-Nitro-2-[(4'-methoxy)-phenoxy]-methanesulfonanilide derivatives and their pharmaceutical use
03/15/2007US20070060543 Aminated complex-type sugar chain derivatives and process for the production thereof
03/15/2007US20070060542 Method for preventing vascular disease
03/15/2007US20070060541 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections
03/15/2007US20070060540 Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
03/15/2007US20070060538 Gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening
03/15/2007US20070060535 Targeted delivery of antiviral compounds through hemoglobin bioconjugates
03/15/2007US20070060534 Anthracycline analogs
03/15/2007US20070060533 Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor
03/15/2007US20070060532 Use of metformin and orlistat for the treatment or prevention of obesity
03/15/2007US20070060531 Pyrazole derivative, drug composition containing the same and production intermediate therefor
03/15/2007US20070060530 Administration of dipeptidyl peptidase inhibitors
03/15/2007US20070060529 Administration of dipeptidyl peptidase inhibitors
03/15/2007US20070060528 Administration of dipeptidyl peptidase inhibitors
03/15/2007US20070060523 Preparation of poly(4-aminopyrrole-2-carboxamide) having the terminal amide group substituted with a 2-amidinoethyl- group; amidating the carbonyl chloride with 2-aminopropionitrile and subjecting the product to the Pinner reaction
03/15/2007US20070060521 Inhibition of STAT3 signal transduction for human cancer therapy
03/15/2007US20070060520 Use of anti-prolactin agents to treat proliferative conditions
03/15/2007US20070060511 Combinations of immunosupressive agents for the treatment or prevention of graft rejections
03/15/2007US20070060510 for complex formation of hepatitis C non-structural protein-3 (NS3) with NS4A; enhancing the proteolytic efficacy at all of the sites; prevent reproduction of hepatitis virus
03/15/2007US20070060509 Endoparasiticidal compositions for topical application
03/15/2007US20070060505 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections
03/15/2007US20070060504 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections
03/15/2007US20070060503 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections
03/15/2007US20070060502 Substituted propane phosphinic acid derivatives
03/15/2007US20070060501 Methods and therapies for potentiating a therapeutic action of an opioid receptor agonist and inhibiting and/or reversing tolerance to opioid receptor agonists
03/15/2007US20070060499 Chloroquine combination drugs and methods for their synthesis
03/15/2007US20070060498 2' and 3'-Prodrugs of 1', 2', 3' or 4'-branched beta -D or beta -L nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses that replicate through an RNA dependent RNA reverse transcriptase; administering interferons as second antivirus agent
03/15/2007US20070059836 Genetic engineering; preventing the proliferation of neoplastic cells; cancer;
03/15/2007US20070059831 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
03/15/2007US20070059828 Carrier for nucleic acid molecule delivery
1 ... 3837 3838 3839 3840 3841 3842 3843 3844 3845 3846 3847 3848 3849 3850 3851 3852 3853 3854 3855 3856 3857 ... 7860